In patients with poor cytogenetic risk, patients with IDH mutations treated with Venetoclax plus LDAC had a CR/CRi rate of 57% compared to CR/CRh rate of 42% in AML patients treated with ivosidenib (IDH1 inhibitor) [48,49]. The gene discussed is IDH2; the disease is acute myeloid leukemia.